Reuters: Health
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
Belgium's UCB to buy Ra Pharmaceuticals for $2.1 billion
Belgium's UCB to buy Ra Pharmaceuticals for $2.1 billion
Reuters: Health
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
Reuters: Health
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment